Sentence examples for mean relapse rate from inspiring English sources

Summarizing data of six follow-up studies, a mean relapse rate of 26% during the first year was found [9], whereas follow-up studies of longer duration have reported relapse rates between 20 and 60% [11 17].

Anyway, our relapse rate of 34% is in fact somewhat lower than the mean relapse rate of 41% (range 21 60%) reported in seven previous studies with a follow-up of at least 4 years (Table 4) [11–17].

A statistically significant reduction in the mean relapse rate in the 2 years after onset of treatment was observed in the three group of patients: Copaxone daily (dly) 1.1±0.6 (p=0.0001); Copaxone alternate (alt) 0.9±0.6 (p=0.0004) and IFNβ-1b 1.2±0.7 (p=0.0001).

Attack frequency ranged from 1 to 8 with the mean relapse rate being 0.93 attacks/year.

In the year prior to natalizumab treatment, 57.7% (124/215) had ≥2 relapses, and the mean relapse rate was 1.77.

During the overall relapsing remitting phase, 1882 attacks were documented with a mean relapse rate of 0.65 attacks/year.

Mean relapse rates were 0.16 and 0.32 in the mitoxantrone glatiramer acetate and glatiramer acetate groups.

The first stage of the quantitative data analysis will describe participants' responses to the continuous variables, i.e. KASQ, PANSS, FBIS and S-CQOL scores and patients' total and mean relapse rates.

In this observational study [ 5], 22 patients with a very active form of RRMS (i.e., a mean annual relapse rate of 2.9 and mean increase of 2.2 in the EDSS score within the 12 months before treatment) received five daily doses of alemtuzumab at 20 mg administered by intravenous infusion over 4 h preceded by a 1-h infusion of methylprednisolone at 1 g.

The authors found a mean cumulative relapse rate of 52% (ranging from 0% to 100%) over a mean follow-up period of 6.3 months (ranging from 0.5 to 24 months) for patients withdrawn from antipsychotics, versus 16% for those patients who continued to receive maintenance antipsychotic treatment.

In the study population as a whole, the mean annualized relapse rate ± standard deviation (SD) was 1.46±1.1 in the year prior to atorvastatin treatment and 0.68±0.99 during atorvastatin treatment (p<0.001).